Compare Dishman Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SANOFI INDIA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SANOFI INDIA DISHMAN PHARMA/
SANOFI INDIA
 
P/E (TTM) x 25.1 40.3 62.2% View Chart
P/BV x 3.3 7.1 47.4% View Chart
Dividend Yield % 0.7 1.2 53.9%  

Financials

 DISHMAN PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SANOFI INDIA
Dec-18
DISHMAN PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3746,840 5.5%   
Low Rs1294,630 2.8%   
Sales per share (Unadj.) Rs197.81,203.1 16.4%  
Earnings per share (Unadj.) Rs21.2165.3 12.8%  
Cash flow per share (Unadj.) Rs34.7209.9 16.5%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.81.5 54.3%  
Book value per share (Unadj.) Rs179.9963.6 18.7%  
Shares outstanding (eoy) m80.6923.03 350.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.8 26.7%   
Avg P/E ratio x11.934.7 34.2%  
P/CF ratio (eoy) x7.227.3 26.5%  
Price / Book Value ratio x1.46.0 23.5%  
Dividend payout %9.450.8 18.6%   
Avg Mkt Cap Rs m20,306132,078 15.4%   
No. of employees `0000.83.3 25.1%   
Total wages/salary Rs m5,3554,068 131.6%   
Avg. sales/employee Rs Th19,252.78,393.8 229.4%   
Avg. wages/employee Rs Th6,459.51,232.4 524.2%   
Avg. net profit/employee Rs Th2,064.11,153.0 179.0%   
INCOME DATA
Net Sales Rs m15,96127,708 57.6%  
Other income Rs m265897 29.6%   
Total revenues Rs m16,22628,605 56.7%   
Gross profit Rs m4,1036,235 65.8%  
Depreciation Rs m1,0911,027 106.2%   
Interest Rs m9447 13,491.4%   
Profit before tax Rs m2,3346,098 38.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,292 27.2%   
Profit after tax Rs m1,7113,806 45.0%  
Gross profit margin %25.722.5 114.2%  
Effective tax rate %26.737.6 71.1%   
Net profit margin %10.713.7 78.0%  
BALANCE SHEET DATA
Current assets Rs m11,01815,922 69.2%   
Current liabilities Rs m9,5176,235 152.6%   
Net working cap to sales %9.435.0 26.9%  
Current ratio x1.22.6 45.3%  
Inventory Days Days11064 173.6%  
Debtors Days Days3521 167.0%  
Net fixed assets Rs m16,3047,539 216.3%   
Share capital Rs m161230 70.2%   
"Free" reserves Rs m12,90721,962 58.8%   
Net worth Rs m14,51622,192 65.4%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80529,839 99.9%  
Interest coverage x3.5872.1 0.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.9 57.7%   
Return on assets %8.912.8 69.7%  
Return on equity %11.817.2 68.7%  
Return on capital %17.527.5 63.7%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9527,587 65.3%   
Fx outflow Rs m6977,145 9.8%   
Net fx Rs m4,255442 962.6%   
CASH FLOW
From Operations Rs m2,7863,739 74.5%  
From Investments Rs m-1,529-731 209.2%  
From Financial Activity Rs m-941-1,972 47.7%  
Net Cashflow Rs m3161,036 30.5%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 3.7 14.4 25.7%  
FIIs % 12.7 14.6 87.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 15,184 304.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling; Sensex Down 235 Points(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading on a mixed note with stocks in the IT sector.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Nov 22, 2019 | Updated on Nov 22, 2019

PFIZER share price has hit an all time high at Rs 4,189 (up 0.6%). The BSE HEALTHCARE Index is up by 0.3%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 0.6%) and SANOFI INDIA (up 0.4%). The top losers include CADILA HEALTHCARE (down 0.1%) and GSK PHARMA (down 0.2%).

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - ALEMBIC LTD COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS